Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
3
Story being shared
GSK's anthrax drug raxibacumab wins support of FDA panel
An FDA advisory panel recommended the approval of GlaxoSmithKline's monoclonal antibody raxibacumab as a therapy for inhalation anthrax. The FDA is expected to decide on the drug's approval by Dec. 15.
Or we can send an email on your behalf